Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Seyed Jafari, S. Morteza, Feldmeyer, Laurence, Bossart, Simon, Simon, Dagmar, Schlapbach, Christoph, Borradori, Luca
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7879677/
https://ncbi.nlm.nih.gov/pubmed/33584689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.611549
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars